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Introduction
Type 1 diabetes (T1D) is an autoimmune disease 
where targeted destruction of pancreatic β-cells 
results in insulin (INS) deficiency and, conse-
quently, hyperglycaemia. Longstanding hypergly-
caemia leads to the accumulation of advanced 
glycation end-products and uncontrolled oxida-
tive stress,1 which have a detrimental effect on the 
mitochondria function and amino acids metabo-
lism in myocytes and neurons of the peripheral 
and central nervous system.2–4 Hence, chronically 
elevated blood glucose (BG) is a major risk factor 
for cognitive and neuromuscular dysfunction.5,6 
Patients with T1D are often found with muscle 
atrophy and reduced muscle strength, neuropa-
thy, cognitive and behavioural problems.6,7 
Therefore, maintaining BG and haemoglobin 
A1c (HbA1c) near the recommended level 
(preprandial BG 80–130 mg/dl, postprandial 
BG < 180 mg/dl and HbA1c < 7.0%) is a major 
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Abstract
Aim: This study aimed to determine the effect of moderate intensity continuous exercise (Ex) 
and hypoxia (Hyp) on serum brain-derived neurotrophic factor (BDNF), insulin-like growth 
factor-1 (IGF-1) and its binding protein-3 (IGFBP-3), irisin and cytokines levels in patients with 
type 1 diabetes (T1D).
Methods: A total of 14 individuals with T1D (age: 28.7 ± 7.3 years) and 14 healthy adults 
(age: 27.1 ± 3.9 years) performed 40-min continuous Ex at moderate intensity (50% lactate 
threshold) on a cycle ergometer in normoxia (Nor) and Hyp (FiO2 = 15.1%) Biochemical factors, 
glucose concentrations and physiological variables were measured at rest, immediately and 
up to 24 h after both Ex protocols.
Results: Patients with T1D had significantly lower pre-Ex serum concentrations of BDNF 
(p < 0.05, p < 0.01), and total IGF-1 (p < 0.001, p < 0.05) and significantly higher irisin levels 
(p < 0.05, p < 0.01) in Nor and Hyp, compared with healthy subjects. Ex significantly increased 
in T1D group serum BDNF (in Nor only p < 0.05) and total IGF-1 levels in Nor and Hyp 
(p < 0.001 and p < 0.01, respectively). Immediately after Ex in Hyp, freeIGF-1 (p < 0.05) and 
irisin levels (p < 0.001) were significantly higher compared with the levels induced by Ex alone. 
Free IGF-1 and irisin serum levels remained elevated in 24 h post-Ex in Hyp. In T1D, significant 
blood glucose (BG) decrease was observed immediately after Ex in Hyp (p < 0.001) and in 24 h 
recovery (p < 0.001) compared with pre-Ex level.
Conclusion: The study results suggest that moderate intensity continuous Ex has beneficial 
effect on BDNF and IGF-1 levels. Ex in hypoxic conditions may be more effective in increasing 
availability of IGF-1. The alterations in the post-Ex irisin levels and IGF-1 system may be 
contributing to more effective glycaemia control in patients with T1D.
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goal of the therapy and long-term management of 
the disease.8,9 Sufficient INS therapy and regular 
physical activity (PA) and exercise (Ex) are rec-
ommended as an integral part of the treatment 
and prevention of diabetes-related complications 
in T1D.9–11
During Ex, contracting skeletal muscles cause an 
increase in glucose transport into the cell, via the 
INS-independent pathway, enhanced synthesis of 
glucose transporters (i.e. GLUT-4) and increased 
INS sensitivity, all of which can decrease INS 
requirements in diabetes mellitus treatment.3,4,12 
Furthermore, skeletal muscle produces and releases 
myokines that exhibit autocrine, paracrine or endo-
crine effects.13,14
Irisin is a recently identified myokine that increases 
energy expenditure through promoting mitochon-
drial biogenesis or metabolic gene expression in 
skeletal muscle,15,16 and plays a key regulatory role 
in browning of white adipose tissue.17 Irisin has 
also been shown to stimulate muscle growth-
related genes in healthy humans,18 which would be 
of importance for patients with T1D suffering with 
muscle atrophy and reduced muscle strength. 
Faienza et  al. observed that elevated irisin levels 
were associated with better glycaemic control and 
bone health in children with T1D.19 Espes et al. 
found a negative correlation between irisin and 
INS requirements in women with T1D.20
Insulin-like growth factor (IGF-1) has been iden-
tified as a myokine that controls muscle growth 
and plays an essential role in maintaining adequate 
functioning of the neuromuscular system.2,21–23 
IGF-1 and its binding proteins contribute to the 
considerable strength gain and bone metabolism 
reported in patients with T1D.24 Since IGF-1 is 
an important autocrine/paracrine factor, its 
reduced expression and serum concentration in 
patients with T1D have been implicated in pro-
gressive neuropathy and muscle atrophy.2,6
With its important role in maturation, neuronal 
repair and plasticity of the central nervous sys-
tem, brain-derived neurotrophic factor (BDNF) 
is a crucial neurotrophic factor also secreted by 
contracting skeletal muscles.25,26 Studies have 
shown that Ex stimulates expression of BDNF 
and its receptors in the brain,27,28 and increases 
serum and plasma BDNF levels in healthy indi-
viduals.29,30 Low plasma BDNF levels and an 
inverse correlation between BDNF and fasting 
glucose were observed in patients with type 2 dia-
betes (T2D).31 Therefore, this myokine may be a 
good predictor of metabolic risk and impaired 
neuromuscular function.31
It is now widely accepted that Ex and PA should be 
an integral part of the treatment for T1D,9,12 
although Ex and PA may lead to the development of 
glycaemic disorders, such as hypo- or hyperglycae-
mia.1 In order to increase the therapeutic value of 
Ex and PA, studies have been conducted to assess 
the metabolic effects of inhaled air with reduced 
oxygen concentration, hence inducing hypoxia 
(Hyp) to facilitate improved glucose control.
The effectiveness of interval Hyp, Hyp training 
and Hyp and single Ex in increasing cardiorespi-
ratory, metabolic and glycaemic control, in 
healthy individuals and patients with diabetes has 
been demonstrated in recent studies.32–34 The 
studies have shown that Hyp stimulates glucose 
transport in INS-resistant human skeletal mus-
cles and, when combined with Ex, improves INS 
sensitivity in T2D and prevents vascular compli-
cations in T1D.34–36 Hypoxic Ex training signifi-
cantly increased serum irisin concentrations in 
diet-induced obese rats.37 A study by Hall et al. 
demonstrated that 40 min of continuous Ex at 
moderate intensity (50% lactate threshold: LAT), 
as well as high intensity (120% LAT) intermittent 
(4 × 5 min intermittent with 5 min rest) Ex during 
Hyp, improved glycaemia and had beneficial 
effects on the concentrations of selected markers 
of vascular function in patients with T1D.34 
Furthermore, Ex with Hyp contributed to reduc-
ing serum levels of proinflammatory cytokine 
tumour necrosis factor alpha (TNF-α),34,38 and 
increased the activity of erythrocytes NO synthase 
levels in patients with T1D,38 potentially leading 
to beneficial changes in skeletal muscle oxygen 
capacity. These benefits were also observed in 
animal studies, where the exposure of rats with 
streptozotcin-induced T1D to hypobaric Hyp 
increased capillarity, reduced tissue injury and 
helped maintain glucose homeostasis.39,40 
Although Ex and PA are widely recommended in 
T1D treatment,9,10,12 the fear of hypoglycaemia 
often stops patients with T1D from participating 
regularly.41 More scientific evidence for the role 
of Ex in preventing diabetes-related muscle atro-
phy and neuropathy is needed to encourage 
patients to be regularly physically active. 
Therefore, the aim of this study was to assess the 
effects of continuous Ex performed in hypoxic 
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conditions on serum levels of selected myokines 
and proinflammatory cytokines involved in regu-
lating neuromuscular function in patients with 
T1D.
Materials and methods
Subjects
A total of 14 (8 males and 6 females) patients 
with T1D treated at the Diabetes Clinic of the 
Silesian Centre, who fulfilled the following crite-
ria were selected in this study: with confirmed 
T1D (ADA criteria),9 no evidence of diabetic 
complications, no personal history of other 
 metabolic or cardiovascular diseases, no acute 
infection 1 week prior to the study. Moreover, 
only patients with at least a good Ex tolerance 
 (maximal oxygen uptake VO2max > 31 ml/kg/min 
for females and VO2max > 37 ml/kg/min for 
males) were included in this study (Table 1).42 
The mean blood haemoglobin A1c (HbA1c) level 
was 7.2 ± 0.6%, the minimum and maximum 
were 6.1% and 8.2%, respectively. Two patients 
had HbA1c > 7.5% and one HbA1c > 8.0%. The 
patients had been suffering from the disease for 
12.0 ± 6.0 years (Table 1). In the study group, 
50% of the patients were using continuous subcu-
taneous INS infusion (CSII) (rapid-acting INS: 
Humalog, NovoRapid or Apidra) and the other 
half multiple daily INS injections (MDII) with 
long-acting (Lantus or Levemir) and rapid-acting 
(NovoRapid) INS. The maximum glucose-lower-
ing effect of all three rapid-acting types of INS 
occurs between 1 and 3 h and INS effect lasts 
3–5 h. For the long-acting INS, the peak effect is 
observed after 6–14 h (Levemir only, with Lantus 
having no peak effect) and duration of action is 
between 16 and 20 (Levemir) and 20–24 h 
(Lantus).43 The control group (CG) consisted of 
14 healthy individuals (9 males and 5 females), 
without impaired glucose tolerance (Table 1). 
For the entire duration of the experiment, all 
patients were asked to consume the same bal-
anced diet. No caffeine, antioxidants supplements 
or alcohol were permitted 48 h before and during 
the experiment. A few days prior to the study the 
subjects were asked to refrain from PA/Ex. All 
Table 1. Anthropometric characteristics and physiological variables before (rest) and in response to graded Ex test (max) of T1D and CG.
Variable T1D n = 14 CG n = 14 p 95% CI for differences
Mean SD Min–Max Mean SD Min–Max Mean 
differences
Lower 
bound
Upper 
Bound
Age (years) 28.7 7.3 18.0–43.0 27.1 3.9 21.0–45.0 0.070 1.6 1.5 3.2
BMI (kg/m2) 24.1 3.2 18.1–29.9 23.2 2.4 19.7–27.9 0.300 0.9 –0.9 2.7
WHR 0.9 0.1 0.8–1.0 0.8 0.1 0.7–0.9 0.010 0.1 0.0 0.1
FFM (kg) 62.3 12.7 41.6–84.8 58.5 8.4 43.4–73.7 0.400 3.7 –5.3 12.7
SMM 35.1 7.7 22.7–48.4 33.1 5.1 23.8–42.0 0.400 2.0 –3.4 7.4
TBW (%) 45.7 9.3 30.6–62.3 42.9 6.2 31.9–54.0 0.300 2.8 –3.8 9.4
INS (µIU/ml) 5.4 2.3 3.6–7.9 10.6 3.9 5.2–16.8 0.000 –5.2 –7.6 –2.9
BG (mg/dl) 148.9 19.9 128–168 87.2 8.5 70.0–108 0.000 61.7 47.1 76.4
SBPrest (mmHg) 120.6 14.0 100–142 115.1 15.1 103–128 0.300 5.5 –5.2 16.2
DBPrest (mmHg) 73.9 7.1 70.0–90.0 68.2 7.7 50.0–80.0 0.030 5.7 0.4 11.1
HRrest (b/min) 83.0 9.0 76.0–96.0 84.0 14.0 72.0–98.0 0.800 –1.1 –14.6 12.4
VO2max (ml/kg/min) 41.4 10.9 31.0–58.0 46.6 9.3 32.0–69.0 0.200 –5.3 –13.6 3.0
BG, postprandial blood glucose; BMI, body mass index; CG, control group; CI, confidence interval; DBP, diastolic blood pressure; Ex, exercise; FFM, 
free fat mass; HR, heart rate; INS, postprandial total insulin; Max, maximum; Min, minimum; SBP, systolic blood pressure; SD, standard deviation; 
SMM, skeletal muscle mass; T1D, type 1 diabetes; TBW, total body water; VO2max, maximal oxygen uptake; WHR, waist-hip ratio.
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patients performed self-monitoring of BG levels 
under glycaemia control and recorded results of 
glycaemia measurements, INS dosages and con-
sumption of digestible carbohydrates. All indi-
viduals were instructed to arrive at the laboratory 
at least 1.5 h after breakfast. The patients were 
asked to have the pre-Ex glycaemia in the range of 
100–160 mg/dl. Patients using MDII were advised 
to reduce their pre-Ex meal INS bolus (short-act-
ing INS) by about 50% and those using CSII to 
reduce basal INS infusion also by about 50% 3 h 
before the Ex test and maintain it for 2 h post-
Ex.9,41 This advice was based on the peak and 
duration of action of the rapid-acting INS.43 The 
T1D patients were advised to monitor their gly-
caemia more frequently after the completion of 
Ex to adjust INS dose and carbohydrate intake. 
The assessment of the digestible carbohydrate 
intake was calculated with dedicated software 
(Dietus, B.U.I. InFit. Warsaw, Poland). Body 
composition of all participants was evaluated 
using a model In Body220 analyser (Biospace 
Inc., Seoul, Korea).
All individuals were informed about the aim of the 
research, the possibility of refusal of the participation 
and provided written informed consent. The study 
was approved by The Jerzy Kukuczka Academy of 
Physical Education Bioethical Committee (Ethics 
Committee decision KBN3/2016) and conducted in 
accordance with the Declaration of Helsinki of the 
World Medical Association.
Exercise protocol
The study protocol consisted of two stages and 
four visits to the laboratory. During the first stage, 
all participants were subjected to an incremental 
Ex test in normoxia (Nor) and, after 7 days, in 
normobaric Hyp. At baseline, the cycling ramp 
protocol was used to measure individual aerobic 
performance (maximal oxygen uptake, VO2max) 
and lactate threshold (LAT).42 Based on the val-
ues achieved by each individual LAT load (Watt), 
the relative Ex intensities (50% LAT with a 
cadence maintained in the range of 60–70 rpm) 
were calculated for both oxygen conditions. The 
incremental test started with a 3-min warm-up, 
then intensity was increased by 30 W every 3 min 
up to volitional exhaustion (maximal Ex intensity) 
(Table 2).
Before and during both Ex protocols, heart rate 
(HR) was continuously monitored (PE-3000 
Sport-Tester, Polar Inc. Finland). Blood pressure 
[systolic blood pressure(SBP)/diastolic blood 
pressure (DBP)] was measured in duplicate with 
a sphygmomanometer (HEM-907 XL, Omron 
Corporation, Kyoto, Japan) before and immedi-
ately after Ex. Pulmonary ventilation (VE), oxy-
gen uptake (VO2) and carbon dioxide output 
(VCO2) were measured continuously from the 
sixth minute before the start and throughout each 
stage of the Ex test using the Ergospirometr 
Metalyzer 3B-2R (Cortex, Leipzig, Germany). 
Criteria for the termination of VO2 max included: 
voluntary exhaustion, respiratory ratio equal to or 
exceeding 1.15 (RER ⩾ 1.15), a VO2 plateau and 
blood lactate concentration ⩾8.0 mmol/l.
In the second stage of the study, the subjects partici-
pated in the following: 40 min continuous Ex of a 
moderate intensity (60.0 ± 5.0% VO2max), which 
was equivalent to 50.0% of LAT and 65.0% of 
maximal HR (HRmax). The Ex tests were per-
formed randomly in Nor and Hyp. Hypoxic condi-
tions were characterized by a fractional concentration 
of inspired oxygen (FiO2) of 15.1% and atmos-
pheric pressure (p) of 990 hPa. Produced Hyp was 
equivalent to that at an altitude of 2500 m. Normoxic 
conditions were characterized by FiO2 of 20.9% 
and p = 990 hPa. All Ex sessions were conducted in 
an environmentally controlled chamber using an 
electromagnetically braked cycle ergometer (Lode 
B.V., Groningen, The Netherlands). The Altitude 
Trainer Hypoxico System (HYP-123 Hypoxic 
Generator, LOWOXYGEN Technology GmbH, 
Berlin, Germany) was used to produce the hypoxic 
environment.
Biochemical analyses
Samples of venous blood were collected after 
15 min of rest before Ex test (rest), immediately 
after continuous Ex test (max) and during post-
workout recovery (24 h after the end of the test) in 
Hyp and Nor. During each trial, blood samples 
from the antecubital vein were collected to serum 
separator tubes. All serum samples were left to 
clot at room temperature for 30 min and centri-
fuged for 15 min at 1000 × g. Obtained serum was 
aliquoted into Eppendorf and kept frozen at 
–80°C (for a period not longer than 8 months, 
without repeated freezing) until the analyses for 
concentration of BDNF, IGF-1, IGFBP-3, INS, 
irisin, transforming growth factor beta (TGF-β), 
tumour necrosis factor alpha (TNF-α) and inter-
leukins (Il-6 and Il-1β). Capillary blood was 
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collected from a fingertip for the determination of 
BG and lactate (LA) concentration. Prior to the 
start of Ex test, the concentrations of HbA1c were 
analysed by Ames DCA-2000™ Immunoassay 
Analyser in patients with T1D.
Serum concentrations of BDNF were analysed 
using immunoassays (BDNF Ultrasensitive, 
Human; ELISA Kit, Immuniq, Poland). Intra- 
and inter-assay coefficients of variation for BDNF 
were <8% and <10%, respectively, with sensitiv-
ity 0.06 ng/ml. Serum concentrations of IGF-1 
and IGFBP-3 were analysed by an immunoradio-
metric method (DIAsource, Belgium). Intra- and 
inter-assay coefficients of variation for IGF-1 
were <6% and <8%, respectively, with sensitiv-
ity 7.8 ng/ml. The molar ratio of IGF-1/IGFBP-3 
was evaluated as [IGF-1 (ng/ml) × 0.130]/
[IGFBP-3 (ng/ml) × 0.036], considered as a 
parameter determining the concentration of bio-
logically active free IGF- 1 fraction.
Serum concentrations of total INS were analysed 
by an immunoradiometric method (DIAsource, 
Ottignies-Louvain-la-Neuve, Belgium). The intra- 
and inter-assay variability was less than 5% and 
10%, respectively, with sensitivity at 1 µIU/ml. 
Serum irisin concentration was measured using 
an enzyme-linked immunosorbent assay (Irisin 
Human ELISA, Biovendor, Czech Republic). The 
intra- and inter- assay variations were both <6.8% 
and <9.8%, respectively, with sensitivity 1 ng/ml.
Serum levels of TGF-β were measured by 
enzyme-linked immunosorbent assay ELISA kit 
(BlueGene Biotech, China) and TNF-α by 
immunoassays (DIAsource, Belgium). Serum 
levels of IL-6 and IL-1β levels were measured 
using human IL-6 and IL-1β high-sensitivity 
ELISA kit (Diacone, Besançon, France). Intra- 
and inter-assay coefficients of variation for IL-6 
were <4% and <6%, respectively, with sensitiv-
ity 0.7 pg/ml. Intra- and inter-assay coefficients of 
variation for IL-1β were <5.1% and <8.6%, 
respectively, with sensitivity 0.3 pg/ml. BG con-
centration was measured by enzymatic method 
(glucose dehydrogenase), and BG differences 
before and after both Ex tests were calculated 
(BG decline: ΔBG) (Glucose 201+, HemoCue, 
Ängelholm, Sweden).
Pulse oxygen saturation (SatO2) (pulse oximeter) 
and partial pressure of oxygen (pO2) were meas-
ured in arterialized capillary blood from the 
fingertip (RapidLab 348, Bayer Diagnostics, 
Leverkusen, Germany) (Table 2).
Biochemical analyses were performed in our cer-
tified laboratory fulfilling the requirements of PN 
EN-ISO 9001:2009 (certificate No. 129/2015) 
according to instructions provided by the manu-
facturers of laboratory tests used in this study.
Statistical analysis
Shapiro-Wilk and Levene’s tests were used in 
order to verify the normality, homogeneity and 
sphericity of the samples’ data variances, respec-
tively. The magnitudes of differences between 
results of pre-test and post-test were expressed 
as a standardised mean difference (Cohen effect 
sizes). Descriptive statistics were calculated and 
the results presented as means (x) ± standard 
deviations (SD). One-way analysis of variance 
(ANOVA) was used to compare anthropometric 
and physiological variables between the studied 
groups. The remaining data were analysed by 
means of repeated measures ANOVA followed by 
the Student-Newman-Keuls test when appropri-
ate. The group (T1D group versus CG) was the 
grouping factor. The repetition factors included: 
the Ex test (pre- versus post-Ex, 24 h post-Ex), the 
Ex conditions (Nor versus Hyp) and the pre-Ex 
BG levels. In the T1D group, ANOVA was used 
to analyse the interactions between the type of 
INS treatment (CSII versus MDII) and the Ex 
test and Ex conditions. Spearman’s rank correla-
tion coefficients were used to examine the degree 
of correlation between biochemical variables. The 
significance of the intergroup differences was ver-
ified with the post hoc Bonferroni test. All analyses 
were performed using the Statistica versus 12 sta-
tistical software package (StatSoft, Tulsa, OK, 
USA). Statistical significance was set at p < 0.05.
Results
Participants’ characteristics and BG monitoring
The analysis of somatic indices did not show sig-
nificant differences in body mass index (BMI) and 
body composition variables between patients with 
T1D and the healthy subjects. Patients with diabe-
tes had higher WHR (p < 0.01), higher BG but 
lower INS levels compared with healthy controls. 
All subjects were characterised with normal arterial 
blood pressure and met aerobic fitness criteria 
(Table 1). In our study group there was a 
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non-significant tendency to age difference (p = 0.07) 
between T1D and healthy subjects. VO2max and 
LAT did not show significant differences between 
the groups or in response to Ex test in normoxic 
and hypoxic conditions. Statistical analysis of 
changes in physiological variables after (max) Ex in 
Nor and Hyp showed significant differences in 
maximal VE, SatO2 and pO2 in blood (Table 2).
The statistical analysis did not reveal significant 
differences between postprandial BG before con-
tinuous Ex in Nor and Hyp in T1D group; how-
ever, a tendency to higher BG levels was observed 
before Hyp Ex (p = 0.052) (Table 3). The patients 
were requested to have pre-Ex glycaemia in the 
range of 100–160 mg/dl; however, the mean pre-
Ex BG levels achieved higher values in four 
patients before Nor and in five patients before 
Hyp. In T1D, significant BG decrease was 
observed immediately after Ex in Hyp (p < 0.001) 
and in 24 h recovery (p < 0.001) compared with 
pre-Ex level (Figure 1). A higher BGΔ was 
observed in response to Ex in Hyp compared with 
Nor (66% versus 35% respectively; p < 0.01).
ANOVA revealed a significant main effect of the 
Ex and oxygen conditions on BG concentration 
(F = 8.8, p < 0.02) in the T1D group but not in 
CG (F = 0.5, p = 0.58). In the T1D group, the 
ANOVA result was not significant in response to 
interaction between glycaemia, Ex and oxygen 
conditions on BG level (F = 1.1, p = 0.35) as well 
as the combined effect of type of treatment (CSII 
versus MDII), Ex and BG (F = 3.4, p = 0.08).
Significantly lower INS levels were observed in 
patients with T1D before Ex in Hyp and Nor 
(p < 0.05 and p < 0.01, respectively) and in response 
to both Ex tests (p < 0.05 and p < 0.05, respec-
tively) compared with CG. No significant effect of 
oxygen conditions and Ex on total INS levels were 
observed in T1D (F = 0.18, p = 0.8). In patients 
with T1D, there were no significant differences 
between daily INS dosage, INS dosage at breakfast 
and carbohydrate (CHO) intake (Table 3).
Myokines response to exercises in different 
oxygen conditions
ANOVA revealed a significant main effects of dia-
betes on pre-Ex serum concentration of irisin 
(F = 7.7, p < 0.01) and an interaction between dia-
betes, Ex and oxygen conditions (F = 8.8, p < 0.02) 
on serum irisin levels. A significantly higher serum 
concentration of irisin before Ex in Nor and Hyp 
(p < 0.5, p < 0.01, respectively) and after 24 h recov-
ery (p < 0.001, p < 0.01, respectively) was observed 
in the T1D group compared with the CG. In T1D, 
significantly higher serum levels of irisin in response 
to Ex in Hyp (immediately after Ex) compared with 
Nor were observed (p < 0.001). Ex- and Hyp-
induced irisin levels remained elevated 24 h post-Ex 
Table 2. Physiological variables before (rest), after Ex (max) incremental VO2max tests in Hyp and Nor in both 
groups (mean; SD).
Variable T1D n = 14 CG n = 14
 Hyp Nor p Hyp Nor p
VO2rest (ml/kg/min) 7.1 (0.5) 7.3 (0.6) 0.999 7.1 (0.4) 7.4 (0.5) 0.999
VO2max (ml/kg/min) 43.9 (2.4) 41.4 (10.9) 0.868 46.4 (2.1) 46.6 (9.3) 0.999
VE (l/min) 120.8 (7.0) 101.6 (7.5) 0.007 122.0 (6.0) 102.3 (6.2) 0.007
HRmax (b/min) 178.0 (10.0) 179.0 (12.0) 0.999 181.0 (12.0) 183.0 (11.0) 0.999
LAT (Watt) 146.0 (8.2) 153.7 (10.4) 0.112 147.1 (7.6) 156.0 (9.4) 0.296
LAmax (mmol/l) 9.4 (0.8) 9.5 (0.7) 0.894 9.3 (0.4) 9.4 (0.5) 0.990
SatO2 (%) 90.6 (4.0) 97.0 (3.0) 0.027 92.0 (0.8) 96.8 (1.7) 0.079
pO2max (mmHg) 62.8 (1.8) 87.0 (2.0) 0.012 60.2 (2.0) 87.5 (2.0) 0.011
CG, control group; HR, heart rate; Hyp, hypoxia; LA, blood lactate concentration; LAT, lactate threshold; Nor, normoxia; 
pO2, partial pressure of oxygen in blood; SatO2, oxyhaemoglobin saturation; SD, standard deviation; T1D, type 1 diabetes; 
VE, lung minute ventilation; VO2, oxygen consumption; VO2max, maximal oxygen uptake.
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(Figure 2). In Nor, irisin levels tended to decrease 
immediately after Ex (p = 0.060) and were signifi-
cantly higher after the 24 h recovery compared with 
pre-Ex levels in the T1D group (p < 0.001) (Figure 
2). No significant interactions between type of treat-
ment, Ex and Ex conditions were observed in 
regards to serum irisin levels (F = 0.4, p = 0.69). 
Similarly, no effects of pre-Ex glycaemia on these 
factors were revealed (F = 0.9, p = 0.43).
Significantly lower pre-Ex serum concentrations 
of BDNF (p < 0.05, p < 0.01) and IGF-1 
(p < 0.001, p < 0.05) in Nor and Hyp, respec-
tively, were observed in T1D compared with 
healthy subjects. ANOVA revealed a significant 
effect of the group (F = 25.4, p < 0.001) and Ex 
(F = 8.1, p < 0.01) on serum BDNF levels. Serum 
BDNF levels significantly increased in Nor Ex 
(p < 0.05) and tended to be higher in Hyp Ex 
(p = 0.08) compared with rest values in T1D 
(Figure 3). No significant interactions between Ex 
and Ex conditions (F = 0.2, p = 0.81) and glycae-
mia (F = 1.9, p = 0.17) and these factors and the 
type of treatment (F = 0.5, p < 0.59) in regards to 
serum BDNF levels in T1D group were observed.
ANOVA revealed a significant effect of T1D on 
pre-Ex total IGF-1 levels (F = 17.1, p < 0.001) 
and a combined effect of Ex and diabetes (F = 10.4, 
p < 000) was also found. Ex significantly increased 
total IGF-1 levels in Nor (p < 0.001) and Hyp 
(p < 0.01) but only in T1D group (Figure 4). 
ANOVA revealed significant interaction between 
diabetes, Ex and oxygen conditions (F = 3.9 
p = 0.05). Moreover, significant effect of type of 
INS treatment (pump versus injection) was 
observed on IGF-1 (F = 10.0 p < 0.04) and a 
combined effect of INS treatment and Ex on 
IGF-1 levels (F = 6.4, p < 0.01) with a tendency 
to higher IGF-1 levels in patients using MDII 
(p = 0.11). In the T1D group, Ex-induced 
IGFBP-3 levels were significantly lower in Hyp 
compared with Nor (7193.8 ± 2621.9 versus 
11864.2 ± 2173.6 μmol/l, respectively; p < 0.001). 
ANOVA analysis revealed an interaction between 
the oxygen conditions and diabetes on post-Ex 
freeIGF-1 levels (F = 5.8, p < 0.05). Significantly 
higher freeIGF-1 levels were revealed immediately 
after Ex in Hyp compared with Nor in T1D group 
(p < 0.05). Ex in Hyp and Nor significantly 
decreased freeIGF-1 in CG (p < 0.01) (Figure 5).
Figure 1. BG concentrations at rest, immediately after (max) and in response to 24-h recovery (24 h) of 
continuous Ex in Hyp and Nor in patients with T1D and healthy CG.
*p < 0.05, **p < 0.01, ***p < 0.001 indicate statistically significant differences between T1D and CG; #p < 0.05, ###p< 0.001 
indicate statistically significant differences between pre- and post-Ex.
BG, blood glucose; CG, control group; Ex, exercise; Hyp, hypoxia; Nor, normoxia; T1D, type 1 diabetes.
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Significant interaction effects for the group, Ex 
and oxygen conditions (F = 8.1 p < 0.001) on 
TGF-β serum concentration were found. Pre-Ex 
and post-Ex concentration of TGF- β did not dif-
fer between both groups. TGF-β increased sig-
nificantly in response to Ex in Hyp in CG 
Table 3. BG, INS and CHO intake at breakfast and the day of the Ex test in Hyp and Nor.
Variable T1D n = 14 CG n = 14
 Hyp Nor p Hyp Nor p
BG rest (mg/dl) 179.7 (28.0) 135.4 (26.3) 0.052 85.6 (8.9) 81.0 (23.1) 0.530
BG max (mg/dl) 113.7 (38.7) 101.4 (36.3) 0.430 83.9 (8.7) 78.3 (22.3) 0.380
INS rest (µIU/ml) 6.4 (2.2) 6.2 (4.8) 0.924 10.4 (4.1) 11.2 (3.8) 0.660
INS max (µIU/ml) 6.0 (2.2) 5.6 (3.5) 0.722 8.9 (3.5) 9.8 (3.6) 0.460
INS DB MDII (Us) 4.9 (3.0) 5.3 (3.5) 0.870 – – –
INS DD (MDII, CSII) (Us) 32.1 (12.7) 32.8 (14.5) 0.999 – – –
CHO breakfast (g) 61.5 (31.7) 63.4 (44.9) 0.995 95.9 (33.2) 97.9 (30.5) 0.735
CHO daily (g) 185.7 (75.1) 187.8 (96.8) 0.999 347.9 (136.8) 340.9 (135.5) 0.999
BG, postprandial blood glucose; CG, control group; CHO, carbohydrates; CSII, patients using continuous subcutaneous 
insulin infusion; Hyp, hypoxia; INS, serum level of total insulin; before (rest) and immediately after Ex (max); INS DB, 
insulin dosage at breakfast; INS DD, insulin daily dosage; MDII, multiple daily insulin injections; Nor, normoxia.
Figure 2. Irisin concentrations at rest, immediately after (max) and in response to 24-h recovery of continuous 
Ex in Hyp and Nor in patients with T1D and healthy CG.
+p < 0.05 indicate statistically significant differences between pre- and post-Ex; *p < 0.05, **p < 0.01, ***p < 0.001 indicate 
statistically significant differences between T1D and CG; #p < 0.05, ###p < 0.001 indicate statistically significant differences 
between Hyp and Nor.
CG, control group; Ex, exercise; Hyp, hypoxia; Nor, normoxia; T1D, type 1 diabetes.
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Figure 3. BDNF concentrations at rest, immediately after (max) and in response to 24-h recovery (of 
continuous Ex in Hyp and Nor in patients with T1D and healthy CG.
+p < 0.05 indicate statistically significant differences between pre- and post-Ex; *p < 0.05, **p < 0.01, ***p < 0.001 indicate 
statistically significant differences between T1D and CG; #p < 0.05, ###p < 0.001 indicate statistically significant differences 
between Hyp and Nor.
BDNF, brain-derived neurotrophic factor; CG, control group; Ex, exercise; Hyp, hypoxia; Nor, normoxia; T1D, type 1 diabetes.
Figure 4. IGF-1 concentrations at rest, immediately after (max) and in response to 24-h recovery of continuous 
Ex in Hyp and Nor in patients with T1D and healthy CG.
+p < 0.05 indicate statistically significant differences between pre- and post-Ex; *p < 0.05, **p < 0.01, ***p < 0.001 indicate 
statistically significant differences between T1D and CG; #p < 0.05, ###p < 0.001 indicate statistically significant differences 
between Hyp and Nor.
CG, control group; Ex, exercise; Hyp, hypoxia; IGF-1, insulin-like growth factor-1; Nor, normoxia; T1D, type 1 diabetes.
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Figure 5. IGF-1/IGFBP-3 concentrations at rest, immediately after (max) and in response to 24-h recovery of 
continuous Ex in Hyp and Nor in patients with T1D and healthy CG.
+p < 0.05 indicate statistically significant differences between pre- and post-Ex; *p < 0.05, **p< 0.01, ***p < 0.001 indicate 
statistically significant differences between T1D and CG; #p < 0.05, ###p < 0.001 indicate statistically significant differences 
between Hyp and Nor.
CG, control group; Ex, exercise; Hyp, hypoxia; IGF-1, insulin-like growth factor-1; IGFBP-3, insulin like growth factor binding 
protein; Nor, normoxia; T1D, type 1 diabetes.
Table 4. Cytokine concentrations before (rest), after Ex (max) and 24 h recovery in Hyp and Nor in both groups.
Variable Hyp Nor p 95% CI for differences
 Mean SD Mean SD Mean differences Lower bound Upper bound
T1D group
TGF-βrest (pg/ml) 145.4 32.6 140.5 25.9 0.710 4.9 –22.9 32.7
TGF-βmax (pg/ml) 156.7 42.4 167.9 28.1 0.510 –11.1 –46.9 24.7
TGF-β24h (pg/ml) 131.7 24.1 148.5 31.8 0.110 –16.7 –38.3 4.7
TNF-αrest (pg/ml) 30.0 5.9 34.6 14.3 0.160 –5.6 –13.8 2.6
TNF-αmax (pg/ml) 35.7 19.4 35.5 10.0 0.960 0.2 –10.2 10.7
TNF-α24h (pg/ml) 69.6 52.9 43.0 15.0 0.080 26.5 –4.2 57.3
IL-6rest (pg/ml) 1.1 0.8 1.2 0.7 0.550 –0.5 –0.3 0.1
IL-6max (pg/ml) 1.1 0.7 1.4 0.6 0.170 –0.30 –0.75 0.15
IL-624h (pg/ml) 1.1 0.3 1.2 0.4 0.650 –0.6 –0.3 0.2
IL-1βrest (pg/ml) –0.2 0.9 –0.2 0.9 0.980 –0.001 –0.21 0.21
IL-1βmax (pg/ml) 1.3 1.4 2.1 3.2 0.480 0.8 –3.1 1.5
IL-1β24h (pg/ml) 1.2 1.2 1.1 1.6 0.940 0.0 –1.2 1.3
Healthy CG
TGF-βrest (pg/ml) 118.7 19.8 130.4 16.9 0.150 –11.7 –28.6 5.1
TGF-βmax (pg/ml) 137.8 29.3 120.6 21.7 0.020 17.2 2.1 32.3
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(p < 0.05) (Table 4). ANOVA revealed a signifi-
cant effect for the test conditions (F = 5.1 p < 0.01) 
and interaction effects for group and Ex (F = 3.8, 
p < 0.05) on TNF-α serum concentration. In the 
T1D and CG, a tendency to TNF-α levels to 
increase in the 24 h post-Ex was observed. 
ANOVA and post hoc analysis did not reveal any 
significant effects of the factors or significant dif-
ferences in serum levels of IL-6 and IL-1β in T1D 
group (Table 4). Significant interactions between 
Ex, oxygen conditions and type of INS treatment 
was observed in serum IL-6 (F = 4.7, p < 0.01) 
and 1L-1β levels (F = 3.4, p < 0.04 in T1D. Lower 
post-Ex IL-1β levels were observed in patients 
using MDII in Nor (p < 0.01) and Hyp (p < 0.01) 
compared with patients using CSII.
In T1D and CG groups, continuous Ex combined 
with Hyp significantly reduced SatO2 compared 
with Nor (97.0 ± 0.7 versus 91.0 ± 2.8, p < 0.01 
and 95.6 ± 1.7 versus 91.6 ± 2.6, p < 0.01, 
respectively).
In Hyp, there were positive correlations between 
post-Ex BDNF and total IGF-1 levels in T1D 
group and CG (r = 0.73, p = 0.02 and r = 0.68, 
p = 0.011). Serum pre-Ex BDNF levels were asso-
ciated with BG concentrations in T1D group in 
Nor (r = 0.68, p = 0.04). In the T1D group, 
immediately post-Ex BDNF correlated positively 
with BGΔ in Hyp (r = 0.72, p = 0.03). There were 
no correlations observed in CG.
Discussion
This study aimed to assess the effects of Hyp and 
Ex on myokines and proinflammatory cytokines 
involved in regulating neuromuscular function in 
patients with T1D. The assessment was based on 
the analysis of glycaemia changes and serum con-
centrations of selected myokines (BDNF, IGF-1, 
irisin), and proinflammatory cytokines (IL-6, 
IL-1β, TNF-α, TGF-β) known to be involved in 
regulating muscle and/or nerve cell gro
wth.21,22,44–46 A major finding of the study is that 
continuous Ex in different oxygen conditions 
modified secretion of the factors regulating neu-
romuscular function. Continuous Ex in Nor 
resulted in significant increases in BDNF and 
IGF-1 levels, whereas no significant changes 
occurred in free IGF-1 levels. When Ex was com-
bined with Hyp, a significant elevation of serum 
concentration of free IGF-1 and irisin levels 
immediately after Ex as well as a greater BGΔ 
compared with Ex alone were observed. Hyp 
caused a greater Ex-induced serum IGF-1 level 
increase, whereas no significant changes occurred 
in IGFBP-3 levels. IGF-1/IGFB-3 ratios were 
Variable Hyp Nor p 95% CI for differences
 Mean SD Mean SD Mean differences Lower bound Upper bound
TGF-β24h (pg/ml) 141.3 40.5 127.7 27.9 0.310 13.5 –14.9 41.9
TNF-αrest (pg/ml) 42.1 14.4 33.8 9.7 0.160 8.3 –4.0 20.6
TNF-αmax (pg/ml) 51.7 30.9 62.1 44.9 0.580 –10.2 –50.2 29.8
TNF-α24h (pg/ml) 61.8 43.9 36.3 9.9 0.070 46.9 –2.9 53.8
IL-6 rest (pg/ml) 1.9 1.1 0.9 0.6 0.330 0.3 –0.1 1.6
IL-6max (pg/ml) 1.9 3.1 1.0 0.7 0.320 0.9 –0.9 2.8
IL-624h (pg/ml) 1.6 1.2 0.7 0.6 0.010 0.9 0.2 1.6
IL-1βrest (pg/ml) 2.8 4.5 3.0 3.4 0.890 0.2 –3.7 3.3
IL-1βmax (pg/ml) 2.9 5.8 2.3 3.9 0.790 0.5 –3.9 5.1
IL-1β24h (pg/ml) 2.6 5.4 2.2 4.2 0.850 0.4 –4.1 4.9
24 h, 24 h after the end of the test; CG, control group; Hyp, hypoxia; IL-6, interleukin 6; IL-1β, interleukin 1 beta; max, immediately after Ex; Nor, 
normoxia; rest, before Ex; T1D, type 1 diabetes; TGF-β, transforming growth factor beta; TNF-α, tumour necrosis factor alpha.
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significantly elevated by Hyp. Thus, IGF-1 bioa-
vailability was increased as a result of Hyp com-
pared with Nor in individuals with T1D. It was 
also interesting to note that resting BDNF and 
IGF-1 levels were significantly lower and irisin 
levels significantly higher in patients with T1D 
than in age-matched healthy controls.
Myokines are synthesised and released by con-
tracting myocytes.44 Myokines exhibit an auto-
crine and para/endocrine function regulating the 
metabolism of the muscles and of organs and tis-
sues such as brain, liver and adipose tis-
sue.18,23,31,47,48 In the present study, the profiles of 
most of the selected myokines significantly dif-
fered between the groups. It has been docu-
mented previously that skeletal muscle ability to 
secrete some myokines (BDNF, IGF-1 and irisin) 
may decline with age,39,49,50 and age-related 
changes in skeletal muscles affect individuals 
from approximately the fourth decade of life.51 In 
the present study, there was an insignificant 
(p = 0.07) age difference between the two groups 
and pre-Ex serum levels of the myokines varied. 
Nevertheless, with a mean age of 28.7 (7.3) years, 
comparable skeletal muscle mass (Table 1) and 
miscellaneous serum concentrations of BDNF 
and IGF-1 (decreased) and irisin (increased) in 
T1D compared with healthy subjects, it seems 
that the differences in myokines secretion could 
not be attributed to age difference, but potentially 
to hyperglycaemia. A study by Ates et al. found a 
positive correlation between irisin and HbA1c 
and observed that chronic inflammation and 
autoimmunity seem to increase serum irisin lev-
els. 52 On the contrary, Tentolouris et al. observed 
significantly lower levels of circulating irisin in 
patients with T1D compared with healthy 
adults.53 The authors observed a positive correla-
tion between irisin levels and waist circumference 
in subjects with diabetes.
In the present study, individuals with T1D had a 
higher waist-to-hip ratio (WHR) than healthy 
controls and comparable body fat mass (~18% of 
body mass). The higher irisin levels among T1D 
compared with healthy individuals in the current 
study might be associated with intergroup differ-
ences in WHR; however, other factors should also 
be considered.16,18,54
It has been noted that irisin levels increase in 
response to Ex, and fitness level and BMI were 
identified as significant predictive variables for 
post-Ex irisin concentration in healthy subjects.55 
In our study, in T1D group irisin increased in 
response to Ex in Hyp and remained elevated 
in 24 h post-Ex. The benefits of Hyp should be 
treated with caution as higher irisin levels in 
24 h post-Ex in Nor Ex were also observed. Hyp 
 stimulated irisin secretion in response to Ex more 
 effectively in healthy subjects. These findings sug-
gest that Hyp is an important factor in increasing 
serum levels of irisin. Similarly, significantly higher 
serum irisin levels in response to the 8-week Ex 
training in a Hyp environment compared with Ex 
training alone in obese rats have been reported.37 
Interestingly, serum irisin level decreased post-Ex 
in CG but not in the T1D group, where its levels 
remained elevated. These different responses of 
circulating irisin to Ex protocols in both groups 
suggest either impaired secretion of irisin or irisin 
resistance in T1D group. Ex has been considered 
to be the main factor stimulating the synthesis of 
myokine; nevertheless, inflammation and autoim-
munity, the factors characterising T1D, may also 
play a role.38,52,55
Previous studies have shown that irisin promotes 
glucose uptake in skeletal muscle, thus improving 
glucose metabolism.19,48 In the present study, Ex- 
and Hyp-induced increases in serum irisin were 
observed in parallel with significant BG decrease in 
T1D patients and considered as a positive observa-
tion. It has been suggested recently that irisin plays 
a role in regulating glucose homeostasis through 
inducing translocation of glucose transporter type 
4 (GLUT 4) to skeletal muscle cell membrane and 
by stimulating GLUT 4 expression in human adi-
pocytes.39,40 However, whether it also leads to the 
translocation of GLUT 4 to the membrane and, 
consequently, increased glucose uptake by adipose 
tissue, remains unknown.56
In patients with diabetes, the loss of INS secre-
tion with the consequent dysregulated secretion 
of counter-regulatory hormones (glucagon, cor-
tisol, catecholamines, growth hormone) predis-
pose to an increased risk of Ex-induced glucose 
fluctuations,12 which depend on the initial BG 
levels as well as type of INS therapy.10,11,57 Thus, 
precise Ex recommendations should be tailored 
to meet the specific needs of each individual.41 
As recommended, in patients with T1D, BG 
concentrations should always be checked prior 
to Ex and the target range for pre-Ex BG level is 
between 90 and 250 mg/dl. Appropriate CHO 
intake and adjustment of INS doses to starting 
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BG levels and the intensity of Ex are essen-
tial.9,10,41 The initial BG levels of T1D patients 
tended to be higher before Hyp Ex compared 
with Nor in patients with diabetes. No signifi-
cant interactions between pre-Ex glycaemia, 
oxygen conditions, Ex and BG levels seemed to 
confirm that continuous Ex in Hyp may be more 
effective in reducing hyperglycaemia compared 
with continuous Ex alone. The patients were 
treated with different types of INS therapy 
(pump versus injections and rapid-acting INS 
only versus rapid- and long-acting INS); how-
ever, no significant effect of the type of treat-
ment on pre- and post-Ex BG levels was 
determined. Therefore, the interpretation of BG 
response to Ex with and without Hyp has proven 
to be challenging.
The study patients were found with significantly 
lower serum INS concentrations (hypoinsulinae-
mia) compared with healthy subjects. This obser-
vation could have been a result of pre-Ex 
reduction of INS administration. Nevertheless, 
inadequate adherence to INS therapy cannot be 
ruled out.9
Studies have confirmed that, in patients with T1D 
hypoinsulinaemia, chronic hyperglycaemia and 
eleva tion in IL-6 reduce the synthesis of neuro-
trophic factors such as BDNF and IGF-1,5,7,31,58–60 
leading to muscle atrophy and consequently 
reduced muscle strength and cognitive decline.1,6,60 
Indeed, in the present study, the baseline serum 
BDNF and total IGF-1 concentrations were sig-
nificantly lower in the T1D group compared with 
healthy controls. In the T1D group, IGF-1 
increased significantly in response to both Ex pro-
tocols. The increased total IGF-1 levels and lower 
IGFBP-3 concentrations in response to Ex in Hyp 
suggested a positive effect of the Ex in Hyp on 
IGF-1/IGFBP-3 ratio and the bioavailability of 
IGF-1 in T1D. IGFBPs extend the half-life of 
IGF-1 in the circulatory system, decreasing its 
degradation by proteolysis.61 Thus, it is thought 
that the higher molar ratio of IGF-1/IGFBP-3 due 
to IGFBP-3 proteolysis may contribute to benefits 
of Hyp by increasing free IGF-1 bioavailability. 
Apart from its neurotrophic and neuroregenera-
tive effect, alterations in the IGF-1 system may be 
attributed to better control of glucose homoeosta-
sis,60,62,63 as well as improving endothelial function 
and muscle strength.22,61,64 These IGF-1-induced 
effects will be of great importance for T1D 
patients, who are at higher risk of muscle atrophy 
as well as nervous and cardiovascular system 
complications.
In the present study, serum BDNF levels 
increased significantly in response to continuous 
Ex in Nor and tended to be elevated in Hyp. Due 
to the fact that no functional test of neuromuscu-
lar performance was used in this study, we can 
only speculate that the observed elevated BDNF 
levels might be associated with improved cogni-
tive function. The effect of different forms of aer-
obic Ex on enhanced serum BDNF levels,65 INS 
sensitivity and glucose homeostasis in T1D and 
T2D has been well documented.7,66 In addition, 
BDNF has been shown to protect pancreatic β 
cells. This may be attributed to its effect on 
expression of the genes encoding proteins impli-
cated in stress resistance and cell survival.27,67 It is 
important to point out that some inconsistencies 
in literature data on BDNF benefits can be 
explained by differences in the applied method-
ologies of BDNF assessment (serum versus 
plasma).68 Since peripheral BDNF is stored 
mainly in platelets, serum BDNF may be a more 
reliable method of assessing Ex-induced BDNF 
production.68
The present study revealed a significant positive 
correlation between Ex with Hyp-induced IGF-1 
and BDNF serum levels in patients with T1D. 
The increase of total IGF-1 and free IGF-1 was 
associated with greater glycaemia decline com-
pared with that in response to Ex in Nor. IGF-1 
has been suggested to be a key factor involved in 
the modulation of BDNF and INS signalling 
pathways, contributing to motoneurons remodel-
ling and muscle growth.5,7 Both Ex protocols 
stimulated secretion of IGF-1 and BDNF to a 
similar extent. Nevertheless, Hyp had a significant 
effect on serum free IGF-1 levels, which were sig-
nificantly higher compared with Nor conditions.
It has been shown that hyperglycaemia and Hyp 
increase secretion of cytokines by inflammatory 
cells.60,69 However, in the present study, diabetes 
did not have a significant effect on TNFα, TGF-
β, IL-1β and IL-6 serum concentrations, which 
were similar in both groups. Since the evaluation 
of proinflammatory cytokines is a valuable tool 
for evaluation of the risk of developing diabetes-
related complications,34,65,70,71 the study findings 
suggest that T1D patients may not be at risk of 
developing such complications; however, more 
tests would need to be carried out to confirm that. 
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Interestingly a tendency to IL-6 and IL-1β 
increase and slightly higher serum IGF-1 concen-
trations were observed in patients treated with 
INS pumps compared with those using MDII. 
Still, a question arises whether the method of gly-
caemia management could maintain adequate 
serum myokines concentrations in T1D patients. 
This will require further investigation.
The proinflammatory cytokines analysed are also 
classed as myokines and secreted by working skele-
tal muscles.72 TGF-β and TNF-α tended to increase 
immediately after and 24 h post-Ex, respectively. 
These cytokines are involved in the acute inflamma-
tory response to myocyte microdamage occurring 
during Ex, and in muscle repair and regenera-
tion.73,74 Despite the beneficial role of TNF-α in 
post-Ex muscle repair, its persistent elevated level 
may have a detrimental effect on glucose and lipid 
metabolism.75 Nevertheless, it can be expected that 
regular Ex will have an anti-inflammatory effect and 
reduce TNF-α levels and moreover increase secre-
tion of anti-inflammatory cytokines.76 Whether or 
not this Ex regimen will result in long-term clinical 
benefits needs further investigation.
Conclusion
The study results suggest that a single moderate 
intensity continuous Ex significantly increases 
IGF-1 and BDNF levels and has a beneficial 
effect on serum irisin levels. Ex in hypoxic condi-
tions may be more effective in increasing availa-
bility of IGF-1. The alterations in the post-Ex 
irisin levels and IGF-1 system may be contribut-
ing to more effective glycaemia control in patients 
with T1D.
Limitations
There are several limitations of this study. The 
sample size was small and the patients with T1D 
were slightly older. The low serum INS levels in 
patients with diabetes compared with healthy 
subjects might have had a possible impact on 
Ex-induced biochemical changes. Finally, it is not 
a longitudinal study, which made it impossible to 
observe the clinical impacts of the intervention on 
myokine profiles.
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